Redx Pharma is focused on the discovery and development of novel therapeutics to address areas of high unmet medical need, in cancer and fibrosis. The aim is to develop putative drugs through early trials and then to partner them for late stage development and commercialisation.
They discover and develop proprietary, small molecule drugs to address areas of high unmet medical need in cancer and fibrosis. In cancer, they pursue targeted therapies where a biomarker can potentially be used for selecting those patients that are most likely to benefit from therapy, and/or drugs that are designed to disrupt cancer resistance pathways. In fibrosis, they are focused on developing treatments that will stop and reverse the formation of fibrotic tissue.